Cabazitaxel

Cabazitaxel is an antineoplastic medicine belonging to the taxane class and is used primarily for metastatic castration-resistant prostate cancer in patients previously treated with a docetaxel-containing regimen. It is a semi-synthetic taxane that binds to tubulin and promotes microtubule assembly while preventing their normal breakdown. This interferes with the microtubule processes required for cell division and can inhibit the growth of rapidly dividing cancer cells. Cabazitaxel is administered by intravenous infusion and is generally given in combination with oral prednisone or prednisolone. In current U.S. prescribing information, the usual recommended dose is 20 mg/m² every three weeks as a one-hour intravenous infusion, while 25 mg/m² may be considered in selected patients. Premedication is required to reduce the risk of hypersensitivity reactions, and treatment is given under the supervision of healthcare professionals experienced in chemotherapy. Cabazitaxel is clinically important because it demonstrated activity in metastatic prostate cancer that had progressed after docetaxel treatment, providing another taxane-based treatment option in this setting. Its use requires careful monitoring because severe neutropenia, febrile neutropenia, diarrhea, renal complications, and hypersensitivity reactions can occur.

Cabazitaxel is a semi-synthetic derivative of the taxane family developed to retain antitumor activity in models of resistance to conventional taxanes. Its mechanism is based on binding to tubulin and stabilizing microtubules, thereby interfering with cell division. The pivotal TROPIC phase III trial evaluated cabazitaxel with prednisone in men with metastatic castration-resistant prostate cancer whose disease had progressed after docetaxel and provided the principal clinical evidence supporting its initial regulatory approval. The U.S. FDA granted initial approval for cabazitaxel in June 2010. In the European Union, the European Medicines Agency adopted a positive opinion in January 2011, and marketing authorisation was issued on March 17, 2011. Subsequent clinical development included studies evaluating different cabazitaxel doses and comparisons with other treatments, including the FIRSTANA and CARD trials.

Cabazitaxel is approved for use in adult men with metastatic castration-resistant prostate cancer who have previously received a docetaxel-containing treatment regimen. It is administered in combination with prednisone or prednisolone rather than routinely used as monotherapy in the approved indication. The CARD clinical trial also evaluated cabazitaxel in patients whose metastatic castration-resistant prostate cancer had previously been treated with docetaxel and an androgen-signaling-targeted therapy, supporting its role as an established treatment option in appropriately selected patients. Treatment selection depends on previous therapies, disease characteristics, performance status, organ function, and the patient's ability to tolerate chemotherapy.

Cabazitaxel is administered by intravenous infusion over approximately one hour, generally once every three weeks, together with daily oral prednisone or prednisolone according to the applicable regimen. The current U.S. recommended dose is 20 mg/m² every three weeks, while 25 mg/m² may be used in selected patients at the treating clinician's discretion. Patients should receive appropriate premedication before each infusion, including an antihistamine, corticosteroid, and H2 antagonist, with antiemetic treatment when clinically indicated. Complete blood counts and other laboratory parameters should be assessed before treatment and during therapy. Dose interruption or reduction may be required for significant neutropenia, febrile neutropenia, severe diarrhea, renal complications, or other clinically important toxicities. Dose adjustments are also required in hepatic impairment. Treatment is generally continued according to the clinical response and tolerability while avoiding unacceptable toxicity.

Common adverse effects of cabazitaxel include neutropenia, anemia, diarrhea, nausea, fatigue, asthenia, vomiting, constipation, decreased appetite, abdominal pain, back pain, and hematuria. Reduced blood-cell counts are particularly important because neutropenia can increase the risk of serious infection. Gastrointestinal effects such as diarrhea, nausea, and vomiting may require supportive treatment and, when severe, dose modification or interruption. Fatigue and weakness can also occur during treatment. The frequency and severity of adverse effects vary between patients and may be influenced by age, previous chemotherapy, dose, organ function, and other treatments given with cabazitaxel.

Serious Adverse Events and Warnings

Important serious risks include severe neutropenia, febrile neutropenia, neutropenic infection, hypersensitivity reactions, severe diarrhea and gastrointestinal complications, renal failure, interstitial pneumonitis or other serious respiratory disorders, hemorrhagic cystitis, and embryo-fetal toxicity. Cabazitaxel is contraindicated in patients with neutrophil counts at or below the specified threshold, a history of severe hypersensitivity to cabazitaxel or polysorbate 80-containing medicines, and severe hepatic impairment. Severe hypersensitivity requires immediate interruption of the infusion and appropriate treatment. Patients who develop serious treatment-related toxicity may require dose reduction, treatment interruption, or discontinuation. Particular attention is required in older adults and patients with hepatic, renal, gastrointestinal, pulmonary, or hematologic risk factors.

Before treatment, clinicians should assess complete blood counts, liver and kidney function, hydration status, performance status, infection risk, and relevant gastrointestinal, pulmonary, urinary, and cardiovascular history. Patients with hepatic impairment require specific dose adjustment, and severe hepatic impairment is a contraindication. Primary prophylaxis with granulocyte colony-stimulating factor should be considered or used according to the patient's risk profile and the treatment dose, particularly because severe neutropenia and febrile neutropenia can occur. Strong CYP3A inhibitors should generally be avoided because they may increase cabazitaxel exposure; if concomitant use is unavoidable, dose adjustment may be required. Strong CYP3A inducers may reduce exposure and should also be considered carefully. Cabazitaxel is not a biologic medicine, so conventional pharmacokinetic drug-interaction considerations remain relevant. Live vaccines, including yellow fever vaccine, should not be used when contraindicated during treatment.

Confirm the patient's blood counts, hepatic function, renal status, dose calculation, treatment interval, and concomitant medicines before each cycle. Ensure that appropriate antihistamine, corticosteroid, and H2-antagonist premedication is administered before the infusion and that the patient is observed for hypersensitivity reactions. Counsel patients to report fever, chills, persistent diarrhea, vomiting, reduced urine output, breathing difficulties, bleeding, or symptoms of infection promptly. Review the need for granulocyte colony-stimulating factor prophylaxis, particularly in patients at increased risk of febrile neutropenia. Pharmacists should carefully verify the required dilution and infusion preparation according to the specific product information and remain alert to concentration or product-related medication errors. Coordination between oncology, pharmacy, nursing, and supportive-care teams is important for managing blood-count abnormalities, gastrointestinal toxicity, hydration, and dose modifications.